Nimotuzumab with chemoradiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- After 2 to 4 rounds of induction chemo (with or without immunotherapy), your tumor is stable, has only grown in the local area, or the surgeon says it cannot be removed (with no spread to distant organs).
- You are in generally good health, with a Karnofsky score of 70 or higher, meaning you can care for yourself but may not be able to do normal activities.
- Your blood counts and organ function (kidney, liver) are within safe ranges for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial studies whether adding nimotuzumab (an antibody medicine) to radiation (IMRT) can improve outcomes for older adults with cervical squamous cell cancer. It’s for people who cannot tolerate or choose not to have chemotherapy, and who have eligible health test results for safe treatment.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.